Area of research
Hematology · Cancer Research
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Cancer, Lipids, and Metabolism, and Ferroptosis and cancer prognosis.
Magrolimab plus azacitidine vs physician’s choice for untreated <i>TP53</i>-mutated acute myeloid leukemia: the ENHANCE-2 study
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed <i>IDH1</i> -mutated AML
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients
QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in <i>FLT3</i> -ITD–negative acute myeloid leukemia (AML).
Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in <i>NPM1</i>-mutant AML
Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations
Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, <i>FLT3</i>-ITD-Negative Acute Myeloid Leukemia
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory <i>IDH1</i>-mutated AML
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in <i>FLT3</i> -Mutant Leukemia
A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations
Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia
Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Overlapping features of therapy-related and de novo <i>NPM1</i>-mutated AML
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with <i>TP53</i> mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia